WITHDRAWN: Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups von Wong, N.Z.H., Yap, D.W.T., Ong, R.J.M., Zhao, J.J., Chan, Y.H., Tey, J.C.S., Sundar, R., Lim, J.S.J., Dawood, S.S.

Volltext

P1.15-29 Impact of Radiation Therapy Quality Assurance on Progression-Free and Overall Survival in Randomized Trials of Lung Cancer von Soon, Y.Y., Tan, A., Ng, I., Tan, T.H., Tey, J.C.S.

Volltext

Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups von Wong, N Z H, Yap, D W T, Ong, R J M, Zhao, J J, Chan, Y H, Tey, J C S, Sundar, R, Lim, J S J, Dawood, S S

Volltext

OA09.04 Osimertinib with or without SRS for Brain Metastases from EGFRm NSCLC: Pooled Analysis of Two RCTs von Ho, C., Soon, Y.Y., Nichol, A., Robledo, K., Sahgal, A., Pinkham, M., Melosky, B., Huang, Y., Parmar, A., Solomon, B., Tham, I.W.K., Sacher, A., Tey, J.C.S., Menjak, I., Leong, C.N., Shultz, D., Koh, W.Y., Doherty, M., Ang, Y., Low, J., Yong, C., Lim, M.C., Tan, A.P., Lee, C.K., Soo, R., Lefresne, S., Hegi-Johnson, F.

Volltext

OA22.06 Changes in Cognition after Osimertinib, with or without SRS, in EGFRm NSCLC with Brain Metastases: a Pooled Analysis of RCTs von Soon, Y.Y., Lefresne, S., Robledo, K., Nichol, A., Pinkham, M., Sahgal, A., Lee, C.K., Parmar, A., Huang, Y., Doherty, M., Solomon, B., Shultz, D., Tham, I.W.K., Sacher, A., Tey, J.C.S., Leong, C.N., Koh, W.Y., Ang, Y., Low, J., Yong, C., Lim, M.C., Tan, A.P., Soo, R., Ho, C., Hegi-Johnson, F.

Volltext

Supplementary Material for: Prevention of Venous Neointimal Hyperplasia by a Multitarget Receptor Tyrosine Kinase Inhibitor von Kwon, S.H., Li, L., He, Y., Tey J.C.S., Li, H., Zhuplatov, I., Kim, S.-J., Terry, C.M., Blumenthal, D.K., Shiu, Y.-T.

Volltext bestellen